Risk Adapted Treatment for Muscle Invasive Bladder Cancer After Neoadjuvant Accelerated MVAC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02710734

Recruitment Status : Recruiting

First Posted : March 17, 2016

Last Update Posted : November 17, 2017

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Fox Chase Cancer Center

Study Description

Brief Summary:

The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) chemotherapy. Based on the mutational profile and the post AMVAC TURBT findings, patients will be treated with active surveillance (experimental arm), or standard of care intravesicle therapy, chemoradiation or surgery. We hypothesize that this approach will lead to non-inferior metastasis-free survival at 2 years, while preserving the bladder and thus quality-of-life for a proportion of patients.

Condition or disease	Intervention/treatment	Phase
Urothelial Carcinoma of the Bladder	Drug: Methotrexate Drug: Vinblastine Drug: Doxorubicin Drug: Cisplatin Radiation: Intensity modulated radiation therapy (IMRT) Procedure: Transurethral Resection of Bladder tumor Drug: 5-FU Drug: Mitomycin C	Phase 2

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	38 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase II Trial of Risk Adapted Treatment for Muscle Invasive Bladder Cancer After Neoadjuvant Accelerated MVAC (RAT-MIBC)
Actual Study Start Date :	February 24, 2016
Estimated Primary Completion Date :	April 2020
Estimated Study Completion Date :	April 2023

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Bladder cancer

MedlinePlus related topics: Bladder Cancer

Genetic and Rare Diseases Information Center resources: Transitional Cell Carcinoma

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: CRT Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3	Drug: Methotrexate Administered Day 1 of each 14 day cycle for 3 cycles Drug: Vinblastine Administered Day 1 of each 14 day cycle for 3 cycles Drug: Doxorubicin Administered Day 1 of each 14 day cycle for 3 cycles Drug: Cisplatin Administered Day 1 of each 14 day cycle for 3 cycles Radiation: Intensity modulated radiation therapy (IMRT) 2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday Procedure: Transurethral Resection of Bladder tumor Performed at before and after AMVAC and after chemoradiation and intravesicle therapy Drug: 5-FU Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment Drug: Mitomycin C Intravenous on day 1 with radiation treatment
Experimental: Surveillance Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance	Drug: Methotrexate Administered Day 1 of each 14 day cycle for 3 cycles Drug: Vinblastine Administered Day 1 of each 14 day cycle for 3 cycles Drug: Doxorubicin Administered Day 1 of each 14 day cycle for 3 cycles Drug: Cisplatin Administered Day 1 of each 14 day cycle for 3 cycles Procedure: Transurethral Resection of Bladder tumor Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
Experimental: Intravesicle therapy Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3	Drug: Methotrexate Administered Day 1 of each 14 day cycle for 3 cycles Drug: Vinblastine Administered Day 1 of each 14 day cycle for 3 cycles Drug: Doxorubicin Administered Day 1 of each 14 day cycle for 3 cycles Drug: Cisplatin Administered Day 1 of each 14 day cycle for 3 cycles Procedure: Transurethral Resection of Bladder tumor Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
Experimental: Radical Cystectomy Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy	Drug: Methotrexate Administered Day 1 of each 14 day cycle for 3 cycles Drug: Vinblastine Administered Day 1 of each 14 day cycle for 3 cycles Drug: Doxorubicin Administered Day 1 of each 14 day cycle for 3 cycles Drug: Cisplatin Administered Day 1 of each 14 day cycle for 3 cycles Procedure: Transurethral Resection of Bladder tumor Performed at before and after AMVAC and after chemoradiation and intravesicle therapy

Outcome Measures

Primary Outcome Measures :

Metastasis-free survival (MFS) at 2 years. [ Time Frame: 24 months ]

Secondary Outcome Measures :

Ability to complete of 3 cycles of neoadjuvant AMVAC and chemoradiation therapy with 5-FU and mitomycin C. [ Time Frame: Up to 37 Weeks ]

Other Outcome Measures:

Rate of urothelial carcinoma recurrence in active surveillance patients [ Time Frame: 60 months ]
Overall survival and PFS of the entire cohort [ Time Frame: 60 months ]
toxicity during each treatment arm according to NCI CTCAE v 4.01 criteria [ Time Frame: 24 months ]
Proportion of patients with ≥cT1 disease after TURBT#2 [ Time Frame: up to 22 weeks ]
Proportion of patients requiring a cystectomy, either immediately after TURBT#2 or as salvage after surveillance or CRT [ Time Frame: up to 24 months ]
Endoscopic Tumor Quantification System score at each TURBT [ Time Frame: 24 months ]
At each cystoscopic examination, the location and extent of tumor volume will be visually depicted and graded according to Endoscopic Tumor Quantification System
Quality of life with neoadjuvant AMVAC and subsequent risk-adapted treatment [ Time Frame: 60 months ]
American Urologic Association (AUA) Symptom Index Score, Sexual Health Inventory for Men (SHIM) score or Female Sexual Function Index (FSFI) score

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female patients ≥18 years.
Primary urothelial or predominantly urothelial carcinoma of the bladder.
Histologic evidence of muscularis propria invasion.
AJCC27 clinical stage T2-T4a .
No radiographic evidence of lymph node positivity (N0) or metastatic disease (M0). Clinical lymphadenopathy on staging CT greater than 1.5 cm in short axis must be biopsy proven negative.
ECOG performance status 0, 1, or 2.
Left ventricular ejection fraction ≥ 50% by MUGA or ECHO within 6 months of study entry.
Normal organ and bone marrow function as defined:

Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin ≤ institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN Creatinine Creatinine Clearance ≥ 50 mL/min (calculated using the Cockroft-Gault formula or measured with 24 hour urine collection)

Exclusion Criteria:

Any component of small cell histology.
Prior pelvic radiation therapy or patients who have undergone prior radiation to greater than or equal to 25% of the bone marrow within the past year are excluded due to risk of life threatening myelosuppression
Prior systemic chemotherapy; patients who have received any previous systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible.
Prior or concurrent malignancy of any other site except for non-melanoma skin cancer, unless disease free interval ≥ 5 years.
Patients who have received experimental agents within 4 weeks of study entry.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Adriamycin or Cisplatin or other agents used in the study
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (defined by current oral or intravenous antibiotic therapy), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant women are excluded from this study due to the potential for teratogenic or abortifacient effects of cytotoxic chemotherapy.
Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cytotoxic chemotherapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.
Patients with hydronephrosis that has not been addressed with an intervention such as placement of a stent.
Pregnancy & Women of Childbearing Potential

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02710734

Contacts

Layout table for location contacts

Contact: Daniel Geynisman, MD	215-214-1515	Daniel.Geynisman@fccc.edu

Locations

Layout table for location information

United States, Pennsylvania
Fox Chase Cancer Center	Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Daniel Geynisman, MD 215-728-4300 daniel.geynisman@fccc.edu
Principal Investigator: Daniel Geynisman, MD

Sponsors and Collaborators

Fox Chase Cancer Center

More Information

Layout table for additonal information

Responsible Party:	Fox Chase Cancer Center
ClinicalTrials.gov Identifier:	NCT02710734 History of Changes
Other Study ID Numbers:	GU-086 15-1071 ( Other Identifier: Fox Chase Cancer Center IRB )
First Posted:	March 17, 2016 Key Record Dates
Last Update Posted:	November 17, 2017
Last Verified:	November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No
Product Manufactured in and Exported from the U.S.:		No

Keywords provided by Fox Chase Cancer Center:


Urothelial

Additional relevant MeSH terms:

Layout table for MeSH terms

Urinary Bladder Neoplasms Carcinoma, Transitional Cell Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Urinary Bladder Diseases Urologic Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Doxorubicin Mitomycins Mitomycin Methotrexate	Vinblastine Antibiotics, Antineoplastic Antineoplastic Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Dermatologic Agents Folic Acid Antagonists

To Top